ID   NOS2_HUMAN              Reviewed;        1153 AA.
AC   P35228; A1L3U5; B7ZLY2; O60757; O94994; Q16263; Q16692; Q4TTS5;
AC   Q9UD42;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   10-MAY-2017, entry version 201.
DE   RecName: Full=Nitric oxide synthase, inducible;
DE            EC=1.14.13.39;
DE   AltName: Full=Hepatocyte NOS;
DE            Short=HEP-NOS;
DE   AltName: Full=Inducible NO synthase;
DE            Short=Inducible NOS;
DE            Short=iNOS;
DE   AltName: Full=NOS type II;
DE   AltName: Full=Peptidyl-cysteine S-nitrosylase NOS2;
GN   Name=NOS2; Synonyms=NOS2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Colon adenocarcinoma;
RX   PubMed=7692964; DOI=10.1021/bi00094a017;
RA   Sherman P.A., Laubach V.E., Reep B.R., Wood E.R.;
RT   "Purification and cDNA sequence of an inducible nitric oxide synthase
RT   from a human tumor cell line.";
RL   Biochemistry 32:11600-11605(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7682706; DOI=10.1073/pnas.90.8.3491;
RA   Geller D.A., Lowenstein C.J., Shapiro R.A., Nussler A.K.,
RA   di Silvio M., Wang S.C., Nakayama D.K., Simmons R.L., Snyder S.H.,
RA   Billiar T.R.;
RT   "Molecular cloning and expression of inducible nitric oxide synthase
RT   from human hepatocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:3491-3495(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Chondrocyte;
RX   PubMed=7504305; DOI=10.1073/pnas.90.23.11419;
RA   Charles I.G., Palmer R.M.J., Hickery M.S., Bayliss M.T., Chubb A.P.,
RA   Hall V.S., Moss D.W., Moncada S.;
RT   "Cloning, characterization, and expression of a cDNA encoding an
RT   inducible nitric oxide synthase from the human chondrocyte.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:11419-11423(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Articular chondrocyte;
RX   PubMed=7522054; DOI=10.1016/0167-4838(94)90171-6;
RA   Maier R., Bilbe G., Rediske J., Lotz M.;
RT   "Inducible nitric oxide synthase from human articular chondrocytes:
RT   cDNA cloning and analysis of mRNA expression.";
RL   Biochim. Biophys. Acta 1208:145-150(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LEU-608, AND FUNCTION.
RC   TISSUE=Retina;
RX   PubMed=7528017; DOI=10.1006/bbrc.1994.2633;
RA   Park C.S., Pardhasaradhi K., Gianotti C., Villegas E., Krishna G.;
RT   "Human retina expresses both constitutive and inducible isoforms of
RT   nitric oxide synthase mRNA.";
RL   Biochem. Biophys. Res. Commun. 205:85-91(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-608.
RC   TISSUE=Glioblastoma;
RX   PubMed=7531687;
RA   Hokari A., Zeniya M., Esumi H.;
RT   "Cloning and functional expression of human inducible nitric oxide
RT   synthase (NOS) cDNA from a glioblastoma cell line A-172.";
RL   J. Biochem. 116:575-581(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Airway epithelium;
RX   PubMed=7544004; DOI=10.1073/pnas.92.17.7809;
RA   Guo F.H., de Raeve R.H., Rice T.W., Stuehr D.J., Thunnissen F.B.J.M.,
RA   Erzurum S.C.;
RT   "Continuous nitric oxide synthesis by inducible nitric oxide synthase
RT   in normal human airway epithelium in vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7809-7813(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Cardiac myocyte;
RX   PubMed=9160867; DOI=10.1006/jmcc.1996.0349;
RA   Luss H., Li R.-K., Shapiro R.A., Tzeng E., McGowan F.X., Yoneyama T.,
RA   Hatakayama K., Geller D.A., Mickle D.A.G., Simmons R.L., Billiar T.R.;
RT   "Dedifferentiated human ventricular cardiac myocytes express inducible
RT   nitric oxide synthase mRNA but not protein in response to IL-1, TNF,
RT   IFNgamma, and LPS.";
RL   J. Mol. Cell. Cardiol. 29:1153-1165(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Ogawa Y., Nishijima S., Goto M., Ida M.;
RT   "Cloning and characterization of a novel splice valiant of human
RT   inducible nitric oxide synthase.";
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-221; LEU-608;
RP   ALA-747 AND CYS-1009.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 380-473.
RC   TISSUE=Kidney;
RX   PubMed=7532248; DOI=10.1038/ki.1994.365;
RA   McLay J.S., Chatterjee P., Nicolson A.G., Jardine A.G., McKay N.G.,
RA   Ralston S.H., Grabowski P., Haites N.E., Macleod A.M.,
RA   Hawksworth G.M.;
RT   "Nitric oxide production by human proximal tubular cells: a novel
RT   immunomodulatory mechanism?";
RL   Kidney Int. 46:1043-1049(1994).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 667-831, AND INDUCTION.
RC   TISSUE=Glioblastoma;
RX   PubMed=7528267;
RA   Fujisawa H., Ogura T., Hokari A., Weisz A., Yamashita J., Esumi H.;
RT   "Inducible nitric oxide synthase in a human glioblastoma cell line.";
RL   J. Neurochem. 64:85-91(1995).
RN   [15]
RP   CHARACTERIZATION.
RX   PubMed=7558036; DOI=10.1006/geno.1995.1086;
RA   Bloch K.D., Wolfram J.R., Brown D.M., Roberts J.D. Jr., Zapol D.G.,
RA   Lepore J.J., Filippov G., Thomas J.E., Jacob H.J., Bloch D.B.;
RT   "Three members of the nitric oxide synthase II gene family (NOS2A,
RT   NOS2B, and NOS2C) colocalize to human chromosome 17.";
RL   Genomics 27:526-530(1995).
RN   [16]
RP   CHARACTERIZATION.
RX   PubMed=9721329;
RA   Taylor B.S., Alarcon L.H., Billiar T.R.;
RT   "Inducible nitric oxide synthase in the liver: regulation and
RT   function.";
RL   Biochemistry (Mosc.) 63:766-781(1998).
RN   [17]
RP   INTERACTION WITH SLC9A3R1.
RX   PubMed=12080081; DOI=10.1074/jbc.M205764200;
RA   Glynne P.A., Darling K.E.A., Picot J., Evans T.J.;
RT   "Epithelial inducible nitric-oxide synthase is an apical EBP50-binding
RT   protein that directs vectorial nitric oxide output.";
RL   J. Biol. Chem. 277:33132-33138(2002).
RN   [18]
RP   POLYMORPHISM, AND INVOLVEMENT IN RESISTANCE TO MALARIA.
RX   PubMed=12433515; DOI=10.1016/S0140-6736(02)11474-7;
RA   Hobbs M.R., Udhayakumar V., Levesque M.C., Booth J., Roberts J.M.,
RA   Tkachuk A.N., Pole A., Coon H., Kariuki S., Nahlen B.L.,
RA   Mwaikambo E.D., Lal A.L., Granger D.L., Anstey N.M., Weinberg J.B.;
RT   "A new NOS2 promoter polymorphism associated with increased nitric
RT   oxide production and protection from severe malaria in Tanzanian and
RT   Kenyan children.";
RL   Lancet 360:1468-1475(2002).
RN   [19]
RP   FUNCTION.
RX   PubMed=19688109; DOI=10.1155/2009/345838;
RA   Vuolteenaho K., Koskinen A., Kukkonen M., Nieminen R.,
RA   Paeivaerinta U., Moilanen T., Moilanen E.;
RT   "Leptin enhances synthesis of proinflammatory mediators in human
RT   osteoarthritic cartilage--mediator role of NO in leptin-induced PGE2,
RT   IL-6, and IL-8 production.";
RL   Mediators Inflamm. 2009:345838-345838(2009).
RN   [20]
RP   FUNCTION, INTERACTION WITH S100A8 AND S100A9, ASSEMBLY IN THE
RP   INOS-S100A8/A9 COMPLEX, AND INDUCTION BY LDL.
RX   PubMed=25417112; DOI=10.1016/j.cell.2014.09.032;
RA   Jia J., Arif A., Terenzi F., Willard B., Plow E.F., Hazen S.L.,
RA   Fox P.L.;
RT   "Target-selective protein S-nitrosylation by sequence motif
RT   recognition.";
RL   Cell 159:623-634(2014).
RN   [21]
RP   INDUCTION.
RX   PubMed=25180171; DOI=10.1016/j.redox.2014.06.011;
RA   Cortese-Krott M.M., Kulakov L., Oplaender C., Kolb-Bachofen V.,
RA   Kroencke K.D., Suschek C.V.;
RT   "Zinc regulates iNOS-derived nitric oxide formation in endothelial
RT   cells.";
RL   Redox Biol. 2:945-954(2014).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 74-504.
RX   PubMed=10409685; DOI=10.1074/jbc.274.30.21276;
RA   Li H., Raman C.S., Glaser C.B., Blasko E., Young T.A., Parkinson J.F.,
RA   Whitlow M., Poulos T.L.;
RT   "Crystal structures of zinc-free and -bound heme domain of human
RT   inducible nitric-oxide synthase. Implications for dimer stability and
RT   comparison with endothelial nitric-oxide synthase.";
RL   J. Biol. Chem. 274:21276-21284(1999).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 82-528.
RX   PubMed=10074942; DOI=10.1038/6675;
RA   Fischmann T.O., Hruza A., Niu X.D., Fossetta J.D., Lunn C.A.,
RA   Dolphin E., Prongay A.J., Reichert P., Lundell D.J., Narula S.K.,
RA   Weber P.C.;
RT   "Structural characterization of nitric oxide synthase isoforms reveals
RT   striking active-site conservation.";
RL   Nat. Struct. Biol. 6:233-242(1999).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-679.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [25]
RP   VARIANT LEU-608, AND CHARACTERIZATION OF VARIANT LEU-608.
RX   PubMed=24430113; DOI=10.1038/ctg.2013.17;
RA   Dhillon S.S., Mastropaolo L.A., Murchie R., Griffiths C., Thoeni C.,
RA   Elkadri A., Xu W., Mack A., Walters T., Guo C., Mack D., Huynh H.,
RA   Baksh S., Silverberg M.S., Brumell J.H., Snapper S.B., Muise A.M.;
RT   "Higher activity of the inducible nitric oxide synthase contributes to
RT   very early onset inflammatory bowel disease.";
RL   Clin. Transl. Gastroenterol. 5:E46-E46(2014).
CC   -!- FUNCTION: Produces nitric oxide (NO) which is a messenger molecule
CC       with diverse functions throughout the body (PubMed:7531687,
CC       PubMed:7544004). In macrophages, NO mediates tumoricidal and
CC       bactericidal actions. Also has nitrosylase activity and mediates
CC       cysteine S-nitrosylation of cytoplasmic target proteins such
CC       PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9
CC       transnitrosylase complex involved in the selective inflammatory
CC       stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247'
CC       implicated in regulation of the GAIT complex activity and probably
CC       multiple targets including ANXA5, EZR, MSN and VIM
CC       (PubMed:25417112). Involved in inflammation, enhances the
CC       synthesis of proinflammatory mediators such as IL6 and IL8
CC       (PubMed:19688109). {ECO:0000250|UniProtKB:P29477,
CC       ECO:0000269|PubMed:19688109, ECO:0000269|PubMed:25417112,
CC       ECO:0000269|PubMed:7531687, ECO:0000269|PubMed:7544004}.
CC   -!- CATALYTIC ACTIVITY: 2 L-arginine + 3 NADPH + 4 O(2) = 2 L-
CC       citrulline + 2 nitric oxide + 3 NADP(+) + 4 H(2)O.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413; Evidence={ECO:0000250};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692; Evidence={ECO:0000250};
CC       Note=Binds 1 FAD. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=FMN; Xref=ChEBI:CHEBI:58210; Evidence={ECO:0000250};
CC       Note=Binds 1 FMN. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin;
CC         Xref=ChEBI:CHEBI:59560; Evidence={ECO:0000250};
CC       Note=Tetrahydrobiopterin (BH4). May stabilize the dimeric form of
CC       the enzyme. {ECO:0000250};
CC   -!- ENZYME REGULATION: Regulated by calcium/calmodulin. Aspirin
CC       inhibits expression and function of this enzyme and effects may be
CC       exerted at the level of translational/post-translational
CC       modification and directly on the catalytic activity (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer. Binds SLC9A3R1. Interacts with GAPDH; induced
CC       by oxidatively-modified low-densitity lipoprotein (LDL(ox)).
CC       Interacts with S100A8 and S100A9 to form the iNOS-S100A8/9
CC       transnitrosylase complex. {ECO:0000269|PubMed:25417112}.
CC   -!- INTERACTION:
CC       P04406:GAPDH; NbExp=8; IntAct=EBI-6662224, EBI-354056;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P35228-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35228-2; Sequence=VSP_003582, VSP_003583;
CC   -!- TISSUE SPECIFICITY: Expressed in the liver, retina, bone cells and
CC       airway epithelial cells of the lung. Not expressed in the
CC       platelets.
CC   -!- INDUCTION: By endotoxins and cytokines. Induced by IFNG/IFN-gamma
CC       acting synergistically with bacterial lipopolysaccharides (LPS),
CC       TNF or IL1B/interleukin-1 beta (PubMed:7528267). Down-regulated by
CC       zinc due to inhibition of NF-kappa-B transactivation activity
CC       (PubMed:25180171). By oxidatively-modified low-densitity
CC       lipoprotein (LDL(ox)) (PubMed:25417112).
CC       {ECO:0000269|PubMed:25180171, ECO:0000269|PubMed:25417112,
CC       ECO:0000269|PubMed:7528267}.
CC   -!- POLYMORPHISM: Note=Genetic variations in NOS2 are involved in
CC       resistance to malaria [MIM:611162]. {ECO:0000269|PubMed:12433515}.
CC   -!- SIMILARITY: Belongs to the NOS family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nos2a/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Nitric oxide synthase entry;
CC       URL="https://en.wikipedia.org/wiki/Nitric_oxide_synthase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L24553; AAA36375.1; -; mRNA.
DR   EMBL; L09210; AAA59171.1; -; mRNA.
DR   EMBL; X73029; CAA51512.1; -; mRNA.
DR   EMBL; U05810; AAA56666.1; -; mRNA.
DR   EMBL; U31511; AAB49041.1; -; mRNA.
DR   EMBL; D26525; BAA05531.1; -; mRNA.
DR   EMBL; U20141; AAB60366.1; -; mRNA.
DR   EMBL; AF068236; AAC19133.1; -; mRNA.
DR   EMBL; AB022318; BAA37123.1; -; mRNA.
DR   EMBL; DQ060518; AAY43131.1; -; Genomic_DNA.
DR   EMBL; EU332854; ABY87543.1; -; Genomic_DNA.
DR   EMBL; BC130283; AAI30284.1; -; mRNA.
DR   EMBL; BC144126; AAI44127.1; -; mRNA.
DR   EMBL; S75615; AAD14179.1; -; mRNA.
DR   CCDS; CCDS11223.1; -. [P35228-1]
DR   PIR; A49676; A49676.
DR   RefSeq; NP_000616.3; NM_000625.4. [P35228-1]
DR   RefSeq; XP_011523161.1; XM_011524859.2. [P35228-1]
DR   UniGene; Hs.709191; -.
DR   PDB; 1NSI; X-ray; 2.55 A; A/B/C/D=74-504.
DR   PDB; 2LL6; NMR; -; B=515-531.
DR   PDB; 2NSI; X-ray; 3.00 A; A/B/C/D=74-504.
DR   PDB; 3E7G; X-ray; 2.20 A; A/B/C/D=82-505.
DR   PDB; 3EJ8; X-ray; 2.55 A; A/B/C/D=82-505.
DR   PDB; 3HR4; X-ray; 2.50 A; A/C/E/G=503-715.
DR   PDB; 4CX7; X-ray; 3.16 A; A/B/C/D=74-504.
DR   PDB; 4NOS; X-ray; 2.25 A; A/B/C/D=82-508.
DR   PDBsum; 1NSI; -.
DR   PDBsum; 2LL6; -.
DR   PDBsum; 2NSI; -.
DR   PDBsum; 3E7G; -.
DR   PDBsum; 3EJ8; -.
DR   PDBsum; 3HR4; -.
DR   PDBsum; 4CX7; -.
DR   PDBsum; 4NOS; -.
DR   ProteinModelPortal; P35228; -.
DR   SMR; P35228; -.
DR   BioGrid; 110906; 146.
DR   DIP; DIP-59359N; -.
DR   IntAct; P35228; 4.
DR   STRING; 9606.ENSP00000327251; -.
DR   BindingDB; P35228; -.
DR   ChEMBL; CHEMBL4481; -.
DR   DrugBank; DB01997; 3-Bromo-7-Nitroindazole.
DR   DrugBank; DB08214; 4-(1H-IMIDAZOL-1-YL)PHENOL.
DR   DrugBank; DB07002; 4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile.
DR   DrugBank; DB01835; 4r-Fluoro-N6-Ethanimidoyl-L-Lysine.
DR   DrugBank; DB04534; 5-Nitroindazole.
DR   DrugBank; DB03100; 6-Nitroindazole.
DR   DrugBank; DB02207; 7-Nitroindazole.
DR   DrugBank; DB05252; ACCLAIM.
DR   DrugBank; DB02533; Aminoguanidine.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB07306; ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE.
DR   DrugBank; DB07388; ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE.
DR   DrugBank; DB02234; Ethylisothiourea.
DR   DrugBank; DB05214; KD7040.
DR   DrugBank; DB00125; L-Arginine.
DR   DrugBank; DB00155; L-Citrulline.
DR   DrugBank; DB03953; L-Thiocitrulline.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB02044; N-(3-(Aminomethyl)Benzyl)Acetamidine.
DR   DrugBank; DB03449; N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine.
DR   DrugBank; DB07389; N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE.
DR   DrugBank; DB03144; N-Omega-Hydroxy-L-Arginine.
DR   DrugBank; DB02644; N-Omega-Propyl-L-Arginine.
DR   DrugBank; DB02539; S-Ethylisothiourea.
DR   DrugBank; DB02462; Thiocoumarin.
DR   DrugBank; DB08814; Triflusal.
DR   GuidetoPHARMACOLOGY; 1250; -.
DR   iPTMnet; P35228; -.
DR   PhosphoSitePlus; P35228; -.
DR   SwissPalm; P35228; -.
DR   BioMuta; NOS2; -.
DR   DMDM; 1352513; -.
DR   EPD; P35228; -.
DR   PaxDb; P35228; -.
DR   PeptideAtlas; P35228; -.
DR   PRIDE; P35228; -.
DR   Ensembl; ENST00000313735; ENSP00000327251; ENSG00000007171. [P35228-1]
DR   Ensembl; ENST00000621962; ENSP00000482291; ENSG00000007171. [P35228-2]
DR   GeneID; 4843; -.
DR   KEGG; hsa:4843; -.
DR   UCSC; uc002gzu.4; human. [P35228-1]
DR   CTD; 4843; -.
DR   DisGeNET; 4843; -.
DR   GeneCards; NOS2; -.
DR   H-InvDB; HIX0027239; -.
DR   HGNC; HGNC:7873; NOS2.
DR   HPA; CAB002014; -.
DR   MalaCards; NOS2; -.
DR   MIM; 163730; gene.
DR   MIM; 611162; phenotype.
DR   neXtProt; NX_P35228; -.
DR   OpenTargets; ENSG00000007171; -.
DR   PharmGKB; PA164724093; -.
DR   eggNOG; KOG1158; Eukaryota.
DR   eggNOG; COG0369; LUCA.
DR   eggNOG; COG4362; LUCA.
DR   GeneTree; ENSGT00840000129757; -.
DR   HOVERGEN; HBG000159; -.
DR   InParanoid; P35228; -.
DR   KO; K13241; -.
DR   OMA; KFTNSPT; -.
DR   OrthoDB; EOG091G10Z0; -.
DR   PhylomeDB; P35228; -.
DR   TreeFam; TF324410; -.
DR   BioCyc; MetaCyc:HS00205-MONOMER; -.
DR   BRENDA; 1.14.13.39; 2681.
DR   Reactome; R-HSA-1222556; ROS, RNS production in phagocytes.
DR   Reactome; R-HSA-392154; Nitric oxide stimulates guanylate cyclase.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   SignaLink; P35228; -.
DR   SIGNOR; P35228; -.
DR   ChiTaRS; NOS2; human.
DR   EvolutionaryTrace; P35228; -.
DR   GeneWiki; Nitric_oxide_synthase_2_(inducible); -.
DR   GenomeRNAi; 4843; -.
DR   PRO; PR:P35228; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000007171; -.
DR   CleanEx; HS_NOS2; -.
DR   Genevisible; P35228; HS.
DR   GO; GO:0030863; C:cortical cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IMP:BHF-UCL.
DR   GO; GO:0005622; C:intracellular; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; ISS:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0034618; F:arginine binding; ISS:BHF-UCL.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; ISS:BHF-UCL.
DR   GO; GO:0010181; F:FMN binding; ISS:BHF-UCL.
DR   GO; GO:0020037; F:heme binding; ISS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050661; F:NADP binding; TAS:BHF-UCL.
DR   GO; GO:0003958; F:NADPH-hemoprotein reductase activity; IBA:GO_Central.
DR   GO; GO:0004517; F:nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0034617; F:tetrahydrobiopterin binding; ISS:BHF-UCL.
DR   GO; GO:0006527; P:arginine catabolic process; IDA:BHF-UCL.
DR   GO; GO:0045454; P:cell redox homeostasis; TAS:Reactome.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0042742; P:defense response to bacterium; IMP:BHF-UCL.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; NAS:BHF-UCL.
DR   GO; GO:0002227; P:innate immune response in mucosa; NAS:BHF-UCL.
DR   GO; GO:0072604; P:interleukin-6 secretion; IDA:UniProtKB.
DR   GO; GO:0072606; P:interleukin-8 secretion; IDA:UniProtKB.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IBA:GO_Central.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; IBA:GO_Central.
DR   GO; GO:0018119; P:peptidyl-cysteine S-nitrosylation; ISS:UniProtKB.
DR   GO; GO:0031284; P:positive regulation of guanylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0051712; P:positive regulation of killing of cells of other organism; IMP:BHF-UCL.
DR   GO; GO:0001912; P:positive regulation of leukocyte mediated cytotoxicity; TAS:BHF-UCL.
DR   GO; GO:0032310; P:prostaglandin secretion; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0043457; P:regulation of cellular respiration; TAS:BHF-UCL.
DR   GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IDA:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; IMP:BHF-UCL.
DR   GO; GO:0009617; P:response to bacterium; NAS:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0006801; P:superoxide metabolic process; ISS:UniProtKB.
DR   Gene3D; 3.40.50.360; -; 1.
DR   InterPro; IPR003097; FAD-binding_1.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR001094; Flavdoxin-like.
DR   InterPro; IPR008254; Flavodoxin/NO_synth.
DR   InterPro; IPR001709; Flavoprot_Pyr_Nucl_cyt_Rdtase.
DR   InterPro; IPR029039; Flavoprotein-like_dom.
DR   InterPro; IPR004030; NOS_N.
DR   InterPro; IPR001433; OxRdtase_FAD/NAD-bd.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Pfam; PF00667; FAD_binding_1; 1.
DR   Pfam; PF00258; Flavodoxin_1; 1.
DR   Pfam; PF00175; NAD_binding_1; 1.
DR   Pfam; PF02898; NO_synthase; 1.
DR   PRINTS; PR00369; FLAVODOXIN.
DR   PRINTS; PR00371; FPNCR.
DR   SUPFAM; SSF52218; SSF52218; 1.
DR   SUPFAM; SSF56512; SSF56512; 1.
DR   SUPFAM; SSF63380; SSF63380; 1.
DR   PROSITE; PS51384; FAD_FR; 1.
DR   PROSITE; PS50902; FLAVODOXIN_LIKE; 1.
DR   PROSITE; PS60001; NOS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Calmodulin-binding;
KW   Complete proteome; FAD; Flavoprotein; FMN; Heme; Iron; Metal-binding;
KW   NADP; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome; Zinc.
FT   CHAIN         1   1153       Nitric oxide synthase, inducible.
FT                                /FTId=PRO_0000170930.
FT   DOMAIN      539    677       Flavodoxin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00088}.
FT   DOMAIN      730    970       FAD-binding FR-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00716}.
FT   NP_BIND     623    654       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00088}.
FT   NP_BIND     767    778       FAD. {ECO:0000250}.
FT   NP_BIND     903    913       FAD. {ECO:0000250}.
FT   NP_BIND     978    996       NADP. {ECO:0000250}.
FT   NP_BIND    1076   1091       NADP. {ECO:0000250}.
FT   REGION      509    529       Calmodulin-binding. {ECO:0000255}.
FT   METAL       110    110       Zinc.
FT   METAL       115    115       Zinc.
FT   METAL       200    200       Iron (heme axial ligand).
FT   MOD_RES     234    234       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES     575    575       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q06518}.
FT   MOD_RES     578    578       Phosphoserine; by PKA. {ECO:0000255}.
FT   MOD_RES     892    892       Phosphoserine; by PKA. {ECO:0000255}.
FT   VAR_SEQ     264    288       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.9}.
FT                                /FTId=VSP_003582.
FT   VAR_SEQ     298    311       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.9}.
FT                                /FTId=VSP_003583.
FT   VARIANT     221    221       R -> W (in dbSNP:rs3730017).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_024548.
FT   VARIANT     608    608       S -> L (polymorphism; found in patients
FT                                with very early onset inflammatory bowel
FT                                disease; increases NOS2 activity;
FT                                dbSNP:rs2297518).
FT                                {ECO:0000269|PubMed:24430113,
FT                                ECO:0000269|PubMed:7528017,
FT                                ECO:0000269|PubMed:7531687,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_022127.
FT   VARIANT     679    679       A -> S (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs769900089).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036302.
FT   VARIANT     747    747       T -> A (in dbSNP:rs28944173).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_025020.
FT   VARIANT    1009   1009       R -> C (in dbSNP:rs28944201).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_025021.
FT   CONFLICT     23     23       D -> G (in Ref. 4; AAA56666).
FT                                {ECO:0000305}.
FT   CONFLICT    154    154       F -> L (in Ref. 4; AAA56666).
FT                                {ECO:0000305}.
FT   CONFLICT    177    177       G -> V (in Ref. 4; AAA56666).
FT                                {ECO:0000305}.
FT   CONFLICT    266    266       R -> H (in Ref. 8; AAC19133).
FT                                {ECO:0000305}.
FT   CONFLICT    423    423       L -> I (in Ref. 2; AAA59171).
FT                                {ECO:0000305}.
FT   CONFLICT    439    439       A -> T (in Ref. 8; AAC19133).
FT                                {ECO:0000305}.
FT   CONFLICT    552    552       A -> G (in Ref. 12; AAI44127).
FT                                {ECO:0000305}.
FT   CONFLICT    676    676       T -> I (in Ref. 7; AAB60366).
FT                                {ECO:0000305}.
FT   CONFLICT    800    800       T -> A (in Ref. 4; AAA56666).
FT                                {ECO:0000305}.
FT   CONFLICT    805    805       A -> D (in Ref. 2; AAA59171).
FT                                {ECO:0000305}.
FT   CONFLICT    831    832       FL -> SP (in Ref. 2; AAA59171).
FT                                {ECO:0000305}.
FT   CONFLICT    913    913       S -> P (in Ref. 4; AAA56666).
FT                                {ECO:0000305}.
FT   CONFLICT    933    933       R -> G (in Ref. 2; AAA59171 and 7;
FT                                AAB60366). {ECO:0000305}.
FT   CONFLICT    966    966       G -> A (in Ref. 2; AAA59171 and 7;
FT                                AAB60366). {ECO:0000305}.
FT   CONFLICT    987    987       A -> V (in Ref. 2; AAA59171).
FT                                {ECO:0000305}.
FT   STRAND       85     89       {ECO:0000244|PDB:3E7G}.
FT   TURN         90     92       {ECO:0000244|PDB:3E7G}.
FT   STRAND       95     98       {ECO:0000244|PDB:3E7G}.
FT   HELIX       100    103       {ECO:0000244|PDB:3E7G}.
FT   STRAND      104    106       {ECO:0000244|PDB:4NOS}.
FT   HELIX       123    125       {ECO:0000244|PDB:3E7G}.
FT   HELIX       136    152       {ECO:0000244|PDB:3E7G}.
FT   STRAND      154    156       {ECO:0000244|PDB:1NSI}.
FT   HELIX       159    175       {ECO:0000244|PDB:3E7G}.
FT   HELIX       183    195       {ECO:0000244|PDB:3E7G}.
FT   HELIX       203    205       {ECO:0000244|PDB:3E7G}.
FT   STRAND      210    213       {ECO:0000244|PDB:3E7G}.
FT   HELIX       220    235       {ECO:0000244|PDB:3E7G}.
FT   HELIX       236    238       {ECO:0000244|PDB:3E7G}.
FT   STRAND      243    246       {ECO:0000244|PDB:3E7G}.
FT   STRAND      251    255       {ECO:0000244|PDB:3E7G}.
FT   STRAND      261    265       {ECO:0000244|PDB:3E7G}.
FT   STRAND      269    271       {ECO:0000244|PDB:3E7G}.
FT   STRAND      277    279       {ECO:0000244|PDB:3E7G}.
FT   HELIX       281    283       {ECO:0000244|PDB:3E7G}.
FT   HELIX       284    292       {ECO:0000244|PDB:3E7G}.
FT   STRAND      307    310       {ECO:0000244|PDB:3E7G}.
FT   STRAND      317    319       {ECO:0000244|PDB:3E7G}.
FT   HELIX       323    325       {ECO:0000244|PDB:3E7G}.
FT   STRAND      328    330       {ECO:0000244|PDB:3E7G}.
FT   HELIX       337    342       {ECO:0000244|PDB:3E7G}.
FT   STRAND      345    348       {ECO:0000244|PDB:3E7G}.
FT   STRAND      356    359       {ECO:0000244|PDB:3E7G}.
FT   STRAND      362    365       {ECO:0000244|PDB:3E7G}.
FT   HELIX       375    379       {ECO:0000244|PDB:3E7G}.
FT   HELIX       381    384       {ECO:0000244|PDB:3E7G}.
FT   TURN        386    389       {ECO:0000244|PDB:3E7G}.
FT   HELIX       392    399       {ECO:0000244|PDB:3E7G}.
FT   HELIX       406    408       {ECO:0000244|PDB:3E7G}.
FT   HELIX       410    428       {ECO:0000244|PDB:3E7G}.
FT   HELIX       436    454       {ECO:0000244|PDB:3E7G}.
FT   HELIX       461    464       {ECO:0000244|PDB:3E7G}.
FT   STRAND      467    469       {ECO:0000244|PDB:3E7G}.
FT   HELIX       470    472       {ECO:0000244|PDB:3E7G}.
FT   HELIX       474    477       {ECO:0000244|PDB:3E7G}.
FT   STRAND      486    491       {ECO:0000244|PDB:3E7G}.
FT   HELIX       495    498       {ECO:0000244|PDB:3E7G}.
FT   HELIX       515    534       {ECO:0000244|PDB:3HR4}.
FT   STRAND      538    544       {ECO:0000244|PDB:3HR4}.
FT   STRAND      546    548       {ECO:0000244|PDB:3HR4}.
FT   HELIX       549    561       {ECO:0000244|PDB:3HR4}.
FT   TURN        562    564       {ECO:0000244|PDB:3HR4}.
FT   STRAND      565    571       {ECO:0000244|PDB:3HR4}.
FT   HELIX       572    574       {ECO:0000244|PDB:3HR4}.
FT   HELIX       577    581       {ECO:0000244|PDB:3HR4}.
FT   STRAND      584    591       {ECO:0000244|PDB:3HR4}.
FT   TURN        594    596       {ECO:0000244|PDB:3HR4}.
FT   HELIX       600    602       {ECO:0000244|PDB:3HR4}.
FT   HELIX       603    611       {ECO:0000244|PDB:3HR4}.
FT   STRAND      620    627       {ECO:0000244|PDB:3HR4}.
FT   STRAND      631    633       {ECO:0000244|PDB:3HR4}.
FT   HELIX       636    648       {ECO:0000244|PDB:3HR4}.
FT   STRAND      651    654       {ECO:0000244|PDB:3HR4}.
FT   STRAND      657    660       {ECO:0000244|PDB:3HR4}.
FT   HELIX       665    683       {ECO:0000244|PDB:3HR4}.
FT   HELIX       689    691       {ECO:0000244|PDB:3HR4}.
SQ   SEQUENCE   1153 AA;  131117 MW;  47671E5385CB3A52 CRC64;
     MACPWKFLFK TKFHQYAMNG EKDINNNVEK APCATSSPVT QDDLQYHNLS KQQNESPQPL
     VETGKKSPES LVKLDATPLS SPRHVRIKNW GSGMTFQDTL HHKAKGILTC RSKSCLGSIM
     TPKSLTRGPR DKPTPPDELL PQAIEFVNQY YGSFKEAKIE EHLARVEAVT KEIETTGTYQ
     LTGDELIFAT KQAWRNAPRC IGRIQWSNLQ VFDARSCSTA REMFEHICRH VRYSTNNGNI
     RSAITVFPQR SDGKHDFRVW NAQLIRYAGY QMPDGSIRGD PANVEFTQLC IDLGWKPKYG
     RFDVVPLVLQ ANGRDPELFE IPPDLVLEVA MEHPKYEWFR ELELKWYALP AVANMLLEVG
     GLEFPGCPFN GWYMGTEIGV RDFCDVQRYN ILEEVGRRMG LETHKLASLW KDQAVVEINI
     AVLHSFQKQN VTIMDHHSAA ESFMKYMQNE YRSRGGCPAD WIWLVPPMSG SITPVFHQEM
     LNYVLSPFYY YQVEAWKTHV WQDEKRRPKR REIPLKVLVK AVLFACMLMR KTMASRVRVT
     ILFATETGKS EALAWDLGAL FSCAFNPKVV CMDKYRLSCL EEERLLLVVT STFGNGDCPG
     NGEKLKKSLF MLKELNNKFR YAVFGLGSSM YPRFCAFAHD IDQKLSHLGA SQLTPMGEGD
     ELSGQEDAFR SWAVQTFKAA CETFDVRGKQ HIQIPKLYTS NVTWDPHHYR LVQDSQPLDL
     SKALSSMHAK NVFTMRLKSR QNLQSPTSSR ATILVELSCE DGQGLNYLPG EHLGVCPGNQ
     PALVQGILER VVDGPTPHQT VRLEALDESG SYWVSDKRLP PCSLSQALTY FLDITTPPTQ
     LLLQKLAQVA TEEPERQRLE ALCQPSEYSK WKFTNSPTFL EVLEEFPSLR VSAGFLLSQL
     PILKPRFYSI SSSRDHTPTE IHLTVAVVTY HTRDGQGPLH HGVCSTWLNS LKPQDPVPCF
     VRNASGFHLP EDPSHPCILI GPGTGIAPFR SFWQQRLHDS QHKGVRGGRM TLVFGCRRPD
     EDHIYQEEML EMAQKGVLHA VHTAYSRLPG KPKVYVQDIL RQQLASEVLR VLHKEPGHLY
     VCGDVRMARD VAHTLKQLVA AKLKLNEEQV EDYFFQLKSQ KRYHEDIFGA VFPYEAKKDR
     VAVQPSSLEM SAL
//
